今冬流感将达峰，3款国产新药打硬仗

Group 1 - The flu season in 2025 is expected to peak earlier than previous years, with predictions indicating a peak in mid-December, particularly in Guangdong province [1] - Three new domestic antiviral drugs for influenza have been approved and will compete with existing medications during the flu season, creating a "new and old battle" in the market [1] - The current antiviral market in China is still dominated by Oseltamivir and Baloxavir, despite the introduction of new drugs [1] Group 2 - The classic antiviral drug Oseltamivir is showing signs of decline, as it was unexpectedly excluded from the latest national drug procurement list, replaced by lower-priced generic alternatives [2] - This exclusion means that parents familiar with Oseltamivir will find it difficult to obtain the product in public hospitals over the next year [2]